👌Superb review of #SSc ILD by @sclerodermaUM #ACR21 👉EARLY/SUBCLINICAL is NOT Mild ILD 👉MMF 1st 👉TCZ in combination for progressive phenotype/progression 👉Nintedanib:start slow, uptitrate for GI tolerability 👉Early HSCT referral (early dcSSc, FVC&DLCO 45-80%, Normal🫀) https://t.co/MUOhc3PakH